Add Presentation to Slide Tray Presentation:
Treatment To Prevent Fractures in Men and Women With Low Bone Density or Osteoporosis: An Update
Clinical Questions Addressed by the CER (1 of 5)
Key Question (KQ) 1 asked: What are the comparative benefits in fracture reduction among the following therapeutic modalities for LBD?
- Bisphosphonate medications, specifically: alendronate (Fosamax®, oral); risedronate (Actonel®; oral once-a-week); ibandronate (Boniva®); and zoledronic acid (Reclast®, Zometa®, oral and intravenous)
- Denosumab (Prolia®)
- Menopausal Estrogen therapy for women (numerous brands and routes of administration)
- Parathyroid hormone (PTH): 1–34 PTH (teriparatide; Forteo®)
- Selective estrogen receptor modulators (SERMs), specifically: Raloxifene (Evista®)
- Vitamin D
- Combinations or sequential use of above
- Exercise in comparison to the agents above
Keywords: bone | low bone density | bone density | osteoporosis | fracture | osteopenia | skeletal | bisphosphonates | alendronate | risedronate | soledronic acid | ibandronate | teriparatide | parathyroid hormone | menopause | hormonal | estrogen | SERMs | raloxifene | denosumab | calcitonin | vitamin D | calcium | Fosamax | Actonel | Boniva | Reclast | Zometa | Prolia | Forteo | Evista
- Newberry SJ, Crandall CC, Gellad WG, et al. Treatment To Prevent Fractures in Men and Women With Low Bone Density or Osteoporosis: An Update to the 2007 Report. Comparative Effectiveness Review No. 53 (Prepared by the Southern California Evidence-based Practice Center under Contract No. HHSA 290-2007-10062-I). Rockville, MD: Agency for Healthcare Research and Quality; February 2012. AHRQ Publication No. 12-EHC023-EF. Available at www.effectivehealthcare.ahrq.gov/reports/lbd.cfm.
Your slide tray is being processed.